{"classes":[{"categories":[{"measurements":[{"comment":"Lower and upper limit not reached to insufficient number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Progression free survival rate of GBM participants at 6 months is defined as the percentage of participants without progressive disease per Evaluation Criteria in Solid Tumors (RECIST) 1.1 6 months after starting study treatment. Progressive disease is defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with GBM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"Part B: Glioblastoma Multiforme (GBM)"}],"paramType":"NUMBER","populationDescription":"All treated participants in Part B with GBM without progression per RECIST 1.0 at 6 months","reportingStatus":"POSTED","timeFrame":"From first dose to 6 months","title":"Part B: Progression Free Survival (PFS) Rate at 6 Months for GBM Participants","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}